JP2016521688A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016521688A5 JP2016521688A5 JP2016516198A JP2016516198A JP2016521688A5 JP 2016521688 A5 JP2016521688 A5 JP 2016521688A5 JP 2016516198 A JP2016516198 A JP 2016516198A JP 2016516198 A JP2016516198 A JP 2016516198A JP 2016521688 A5 JP2016521688 A5 JP 2016521688A5
- Authority
- JP
- Japan
- Prior art keywords
- exchanged
- replaced
- ankyrin repeat
- seq
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000012659 Joint disease Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 230000009787 cardiac fibrosis Effects 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 claims description 2
- 206010061989 glomerulosclerosis Diseases 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 102000008102 Ankyrins Human genes 0.000 claims 37
- 108010049777 Ankyrins Proteins 0.000 claims 37
- 150000001413 amino acids Chemical class 0.000 claims 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims 19
- 102000014914 Carrier Proteins Human genes 0.000 claims 17
- 108091008324 binding proteins Proteins 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 230000027455 binding Effects 0.000 claims 3
- 230000003176 fibrotic effect Effects 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 208000034038 Pathologic Neovascularization Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13170056.9 | 2013-05-31 | ||
| EP13170056 | 2013-05-31 | ||
| PCT/EP2014/061368 WO2014191574A1 (en) | 2013-05-31 | 2014-06-02 | Designed ankyrin repeat proteins binding to hepatocyte growth factor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016521688A JP2016521688A (ja) | 2016-07-25 |
| JP2016521688A5 true JP2016521688A5 (OSRAM) | 2018-10-18 |
| JP6486908B2 JP6486908B2 (ja) | 2019-03-20 |
Family
ID=48536726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016516198A Active JP6486908B2 (ja) | 2013-05-31 | 2014-06-02 | 肝細胞増殖因子に結合する設計アンキリン反復タンパク質 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11453708B2 (OSRAM) |
| EP (1) | EP3004152B1 (OSRAM) |
| JP (1) | JP6486908B2 (OSRAM) |
| CN (1) | CN105209483B (OSRAM) |
| WO (1) | WO2014191574A1 (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質 |
| EP2738180A1 (en) | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
| US20170226158A1 (en) * | 2014-08-11 | 2017-08-10 | Medimmune Limited | Intracellular antigen binding |
| SG11201707606RA (en) * | 2015-04-02 | 2017-10-30 | Molecular Partners Ag | Designed ankyrin repeat domains with binding specificity for serum albumin |
| NZ751689A (en) | 2016-09-22 | 2021-07-30 | Molecular Partners Ag | Recombinant binding proteins and their use |
| JP7380999B2 (ja) * | 2018-09-06 | 2023-11-15 | 国立大学法人 東京大学 | 環状ペプチド |
| GB201902392D0 (en) * | 2019-02-21 | 2019-04-10 | Cambridge Entpr Ltd | Modular binding proteins |
| BR112021024231A2 (pt) * | 2019-06-04 | 2022-04-26 | Molecular Partners Ag | Proteínas de ligação fap recombinantes e uso da mesma |
| US20200385488A1 (en) | 2019-06-04 | 2020-12-10 | Molecular Partners Ag | Multispecific proteins |
| US20220298212A1 (en) * | 2019-06-04 | 2022-09-22 | Molecular Partners Ag | Recombinant 4-1bb binding proteins and their use |
| IL293698A (en) | 2019-12-11 | 2022-08-01 | Molecular Partners Ag | Recombinant peptide-mhc complex binding proteins, their production and use |
| AU2021267411A1 (en) | 2020-05-06 | 2022-12-08 | Molecular Partners Ag | Novel ankyrin repeat binding proteins and their uses |
| US20240279309A1 (en) * | 2020-05-14 | 2024-08-22 | Molecular Partners Ag | Recombinant cd40 binding proteins and their use |
| JP2023528204A (ja) | 2020-05-14 | 2023-07-04 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 多選択性タンパク質 |
| EP3957649A1 (en) * | 2020-08-18 | 2022-02-23 | Athebio AG | Improved n-terminal capping modules of ankyrin repeat domains |
| US11981710B2 (en) | 2020-08-18 | 2024-05-14 | Athebio Ag | N-terminal capping modules of ankyrin repeat domains |
| WO2022061240A1 (en) * | 2020-09-21 | 2022-03-24 | The Board Of Trustees Of The Leland Stanford Junior University | Heteromultimeric proteins for reducing ige-dependent allergic effector cell activation |
| US20240108746A1 (en) | 2020-12-16 | 2024-04-04 | Molecular Partners Ag | Novel slow-release prodrugs |
| JP2024509904A (ja) | 2021-03-09 | 2024-03-05 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 新規なＤＡＲＰｉｎに基づく多重特異性Ｔ細胞エンゲージャ |
| JP2024508969A (ja) | 2021-03-09 | 2024-02-28 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 新規のＤＡＲＰｉｎに基づくＣＤ３３エンゲージャ |
| EP4305063A1 (en) | 2021-03-09 | 2024-01-17 | Molecular Partners AG | Protease cleavable prodrugs |
| WO2022190018A1 (en) | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Novel darpin based cd123 engagers |
| EP4323388B1 (en) * | 2021-04-16 | 2025-01-29 | Athebio AG | N-terminal capping modules of ankyrin repeat domains |
| WO2023110983A1 (en) | 2021-12-14 | 2023-06-22 | Molecular Partners Ag | Designed repeat domains with dual binding specificity and their use |
| CA3262553A1 (en) | 2022-08-01 | 2024-02-08 | Molecular Partners Ag | REHEARSAL AREAS DESIGNED WITH MODIFIED CHARGES AND THEIR USE |
| WO2024038307A1 (en) | 2022-08-19 | 2024-02-22 | Novartis Ag | Dosing regimens for sars-cov-2 binding molecules |
| WO2024179981A1 (en) | 2023-02-27 | 2024-09-06 | Molecular Partners Ag | Darpins for use in reducing renal accumulation of drugs |
| WO2025146491A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5291279B2 (ja) | 2000-09-08 | 2013-09-18 | ウニヴェルジテート・チューリッヒ | 反復モジュールを含む反復タンパク質の集合体 |
| KR20130114763A (ko) | 2005-03-31 | 2013-10-18 | 더 제너럴 하스피탈 코포레이션 | Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정 |
| DK1902131T3 (da) | 2005-07-08 | 2010-03-01 | Univ Zuerich | Fag-display under anvendelse af cotranslational translokation af fusionspolypeptider |
| JP2010539915A (ja) | 2007-09-24 | 2010-12-24 | ユニバーシティ・オブ・チューリッヒ | 設計されたアルマジロリピートタンパク質 |
| CN102272148A (zh) | 2008-11-03 | 2011-12-07 | 分子组合公司 | 抑制vegf-a受体相互作用的结合蛋白 |
| WO2010136482A1 (en) | 2009-05-28 | 2010-12-02 | Glaxo Group Limited | Antigen-binding proteins |
| TWI510246B (zh) * | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質 |
| WO2012069557A1 (en) * | 2010-11-24 | 2012-05-31 | Glaxo Group Limited | Multispecific antigen binding proteins targeting hgf |
| KR101782790B1 (ko) | 2010-11-26 | 2017-09-28 | 몰리큘라 파트너스 아게 | 혈청 알부민에 결합하는 설계된 반복 단백질 |
| KR20140039203A (ko) | 2011-04-29 | 2014-04-01 | 얀센 바이오테크 인코포레이티드 | Il4/il13 결합 반복 단백질 및 용도 |
| KR20150023957A (ko) | 2012-06-28 | 2015-03-05 | 몰리큘라 파트너스 아게 | 혈소판-유래 성장인자에 결합하는 설계된 안키린 반복 단백질 |
| EP2738180A1 (en) | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
-
2014
- 2014-06-02 CN CN201480028078.2A patent/CN105209483B/zh active Active
- 2014-06-02 EP EP14727816.2A patent/EP3004152B1/en active Active
- 2014-06-02 WO PCT/EP2014/061368 patent/WO2014191574A1/en not_active Ceased
- 2014-06-02 US US14/891,792 patent/US11453708B2/en active Active
- 2014-06-02 JP JP2016516198A patent/JP6486908B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016521688A5 (OSRAM) | ||
| EA202191418A1 (ru) | Рекомбинантные вирусные векторы и нуклеиновые кислоты для их получения | |
| JP2018511327A5 (OSRAM) | ||
| JP2017048194A5 (OSRAM) | ||
| MX2021006615A (es) | Proteinas de union triespecificas y metodos de uso. | |
| CR20200099A (es) | Muteínas de interleucina 21 y métodos de tratamiento | |
| JP2015522576A5 (OSRAM) | ||
| JP2012511545A5 (OSRAM) | ||
| RU2017134456A (ru) | Рекомбинантные связывающие белки и их применение | |
| JP2016529229A5 (OSRAM) | ||
| JP2019519216A5 (OSRAM) | ||
| WO2017189964A3 (en) | Compositions for the treatment of disease | |
| JP2019506841A5 (OSRAM) | ||
| JP2015227342A5 (OSRAM) | ||
| JP2016515524A5 (OSRAM) | ||
| JP2013172743A5 (OSRAM) | ||
| JP2014510519A5 (OSRAM) | ||
| RU2017114673A (ru) | Слитый белок, наночастица, состоящая из множества мономеров указанного слитого белка, и их применение | |
| JP2017523781A5 (OSRAM) | ||
| JP2018531624A5 (OSRAM) | ||
| JP2017524380A5 (ja) | 腫瘍血管遮断剤であるポリペプチド、遺伝子、発現ベクター、腫瘍血管遮断剤の組成物、及び腫瘍血管遮断剤であるポリペプチドの調製方法 | |
| JP2018537399A5 (OSRAM) | ||
| JP2012513193A5 (OSRAM) | ||
| HRP20200418T1 (hr) | Terapeutska uporaba koštanih morfogenetičkih proteina | |
| RU2019134382A (ru) | Лекарственное средство для лечения фиброзного заболевания |